Andrew T Turrisi

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. ncbi request reprint The treatment of limited small cell lung cancer: a report of the progress made and future prospects
    A T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, POB 250318, Charleston, SC 29425, USA
    Eur J Cancer 38:279-91. 2002
  2. doi request reprint The thrill of victory; the agony of defeat
    Andrew T Turrisi
    Int J Radiat Oncol Biol Phys 70:1300-2. 2008
  3. ncbi request reprint Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
    A T Turrisi
    Medical University of South Carolina, Charleston 29425, USA
    N Engl J Med 340:265-71. 1999
  4. ncbi request reprint The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease
    Andrew T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, P O Box 250318, Charleston, SC 29425, USA
    Respir Care Clin N Am 9:163-90. 2003
  5. ncbi request reprint Limited stage small cell lung cancer: treatment and therapy
    Andrew T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, PO Box 250318, Charleston, SC 29425, USA
    Curr Treat Options Oncol 4:61-4. 2003
  6. doi request reprint Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes
    John M Watkins
    Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    Jpn J Radiol 28:340-8. 2010
  7. pmc Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904
    Jeffrey A Bogart
    Department of Radiation Oncology, State University of New York Upstate Medical University, 750 E Adams St, Syracuse NY 13210, USA
    J Clin Oncol 28:202-6. 2010
  8. ncbi request reprint Southwest Oncology Group: two decades of experience in non-small cell lung cancer
    Andrew T Turrisi
    Department of Radiation Oncology, Karmanos Cancer Center, Wayne State University, 540 E Canfield, 1212 Scott Hall, Detroit, MI 48201, USA
    Semin Oncol 32:S119-21. 2005
  9. ncbi request reprint Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis
    James J Urbanic
    Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    J Thorac Oncol 1:112-9. 2006
  10. pmc Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]
    Michael Mitas
    Departments of Surgery, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Mol Diagn 5:237-42. 2003

Detail Information

Publications25

  1. ncbi request reprint The treatment of limited small cell lung cancer: a report of the progress made and future prospects
    A T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, POB 250318, Charleston, SC 29425, USA
    Eur J Cancer 38:279-91. 2002
    ..New drugs, molecular targeted therapy, immunotherapy and other molecular therapies offer promise and theory, but there is little evidence about their place in the treatment protocols of today...
  2. doi request reprint The thrill of victory; the agony of defeat
    Andrew T Turrisi
    Int J Radiat Oncol Biol Phys 70:1300-2. 2008
  3. ncbi request reprint Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
    A T Turrisi
    Medical University of South Carolina, Charleston 29425, USA
    N Engl J Med 340:265-71. 1999
    ..Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy...
  4. ncbi request reprint The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease
    Andrew T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, P O Box 250318, Charleston, SC 29425, USA
    Respir Care Clin N Am 9:163-90. 2003
    ..Palliative dose schedules are being refined that maximize patient comfort while providing substantial symptom relief...
  5. ncbi request reprint Limited stage small cell lung cancer: treatment and therapy
    Andrew T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, PO Box 250318, Charleston, SC 29425, USA
    Curr Treat Options Oncol 4:61-4. 2003
    ..The role of surgery is of limited value in the unusual cases of mediastinal negative disease, but it is a good treatment for patients with peripheral nodules and sufficient pulmonary function to withstand thoracotomy...
  6. doi request reprint Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes
    John M Watkins
    Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    Jpn J Radiol 28:340-8. 2010
    ....
  7. pmc Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904
    Jeffrey A Bogart
    Department of Radiation Oncology, State University of New York Upstate Medical University, 750 E Adams St, Syracuse NY 13210, USA
    J Clin Oncol 28:202-6. 2010
    ..The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) has not been defined...
  8. ncbi request reprint Southwest Oncology Group: two decades of experience in non-small cell lung cancer
    Andrew T Turrisi
    Department of Radiation Oncology, Karmanos Cancer Center, Wayne State University, 540 E Canfield, 1212 Scott Hall, Detroit, MI 48201, USA
    Semin Oncol 32:S119-21. 2005
    ..Further studies examining the addition of either docetaxel or novel agents to such regimens are underway...
  9. ncbi request reprint Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis
    James J Urbanic
    Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    J Thorac Oncol 1:112-9. 2006
    ..Retrospective analysis of patients with medically inoperable non-small cell lung cancer treated with continuous high-dose external beam radiation therapy at the Medical University of South Carolina...
  10. pmc Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]
    Michael Mitas
    Departments of Surgery, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Mol Diagn 5:237-42. 2003
    ..These results provide evidence that circulating tumor cells can be detected in NSCLC patients by a high throughput molecular technique. Further studies are needed to determine the clinical relevance of gene overexpression...
  11. ncbi request reprint 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808
    Jeffrey A Bogart
    Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Int J Radiat Oncol Biol Phys 59:460-8. 2004
    ..To prospectively evaluate the feasibility of delivering 70 Gy once-daily thoracic radiotherapy (TRT), concurrent with chemotherapy, in the treatment of limited-stage small-cell lung cancer (L-SCLC)...
  12. ncbi request reprint A case against surgery for most IIIa non-small cell lung cancer
    Andrew T Turrisi
    Department of Radiation Oncology, Karmanos Cancer Center, Wayne State University, 540 E Canfield, 1212 Scott Hall, Detroit, MI 48201, USA
    Semin Oncol 32:S6-8. 2005
    ..If there is any benefit to surgery in the IIIa as currently staged, the benefit is very small and is counterbalanced by operative risk...
  13. ncbi request reprint The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer
    Andrew T Turrisi
    Department of Radiation Oncology, Medical University of South Carolina, Charleston, USA
    Suppl Tumori 1:S55-7. 2002
  14. ncbi request reprint Locally advanced esophageal cancer
    Carol A Sherman
    Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
    Curr Treat Options Oncol 3:475-85. 2002
    ..These individuals are best managed with palliative intent. Particular attention should be given to alleviating the common problem of dysphagia, which causes significant morbidity...
  15. ncbi request reprint Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003
    Paul Okunieff
    Department of Radiation Oncology, JP Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Am J Clin Oncol 26:522-9. 2003
    ..This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain...
  16. ncbi request reprint Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019
    Kathy S Albain
    Loyola University Stritch School of Medicine, Maywood, IL, USA
    J Clin Oncol 20:3454-60. 2002
    ....
  17. ncbi request reprint Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    David J Samson
    Technology Evaluation Center, Blue Cross Blue Shield Association, 1310 G St, NW, Washington, DC 20005, USA
    Chest 132:314S-323S. 2007
    ....
  18. ncbi request reprint A review of first-line treatment for small-cell lung cancer
    Nevin Murray
    University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Thorac Oncol 1:270-8. 2006
    ....
  19. ncbi request reprint Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer
    Giorgio V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, Torino, Italy
    Oncologist 8:361-74. 2003
    ....
  20. ncbi request reprint Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer
    David H Johnson
    J Natl Cancer Inst 99:415-8. 2007
  21. ncbi request reprint American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
    David G Pfister
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 22:330-53. 2004
  22. ncbi request reprint Limited-disease small-cell lung cancer research: sense and nonsense
    Andrew T Turrisi
    Int J Radiat Oncol Biol Phys 59:925-7. 2004
  23. ncbi request reprint Small cell lung cancer: state of the art and future perspectives
    Roger Stupp
    Multidisciplinary Oncology Center, University Hospital CHUV, 46, Rue du Bugnon, 1011 Lausanne, Switzerland
    Lung Cancer 45:105-17. 2004
    ..Particular emphasis is given to the importance of concomitant and accelerated radiotherapy and consideration of dose-intensive combination chemotherapy regimens...
  24. ncbi request reprint Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer
    Joost J Nuyttens
    Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
    Radiother Oncol 64:209-14. 2002
    ..To determine acute and late complications for bladder and rectum and to determine dose-volume correlations...
  25. ncbi request reprint Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer
    Andrew T Turrisi
    J Clin Oncol 23:4827-9. 2005